MacroGenics Inc. (NASDAQ:MGNX) traded up 4.3% during trading on Thursday . The stock traded as high as $31.41 and last traded at $31.18, with a volume of 199,439 shares changing hands. The stock had previously closed at $29.89.

Several equities research analysts have commented on the stock. Citigroup Inc. downgraded shares of MacroGenics from a “buy” rating to a “neutral” rating and upped their price objective for the company from $27.00 to $32.00 in a report on Thursday, August 4th. TheStreet raised shares of MacroGenics from a “sell” rating to a “hold” rating in a report on Friday, August 5th. Zacks Investment Research upgraded MacroGenics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 20th. Morgan Stanley reiterated a “hold” rating on shares of MacroGenics in a research report on Thursday, June 30th. Finally, Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of MacroGenics in a research report on Tuesday, June 14th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $38.71.

The company’s market cap is $1.08 billion. The firm has a 50-day moving average of $28.30 and a 200-day moving average of $22.15.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $1.12 EPS for the quarter, topping the consensus estimate of ($0.02) by $1.14. The business earned $80.67 million during the quarter, compared to the consensus estimate of $27.22 million. During the same quarter in the previous year, the business posted ($0.71) earnings per share. MacroGenics’s quarterly revenue was up 1100.4% compared to the same quarter last year. On average, equities analysts anticipate that MacroGenics Inc. will post ($1.80) EPS for the current year.

In other MacroGenics news, SVP Jon Marc Wigginton sold 20,000 shares of the firm’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $30.78, for a total value of $615,600.00. Following the transaction, the senior vice president now directly owns 20,000 shares of the company’s stock, valued at $615,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Lynn Cilinski sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 27th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the vice president now directly owns 6,923 shares in the company, valued at $173,075. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently made changes to their positions in the company. Jennison Associates LLC boosted its position in shares of MacroGenics by 0.3% in the fourth quarter. Jennison Associates LLC now owns 267,408 shares of the biopharmaceutical company’s stock valued at $8,282,000 after buying an additional 909 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of MacroGenics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 58,401 shares of the biopharmaceutical company’s stock valued at $1,809,000 after buying an additional 1,038 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in shares of MacroGenics by 87.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 44,743 shares of the biopharmaceutical company’s stock valued at $1,386,000 after buying an additional 20,929 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in shares of MacroGenics by 94.1% in the fourth quarter. Marshall Wace LLP now owns 93,709 shares of the biopharmaceutical company’s stock valued at $2,902,000 after buying an additional 45,422 shares during the last quarter.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.